TrialGynecologic oncology2021

Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu.

Joan Tymon-Rosario et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.